Placental mesenchymal stem cells suppress inflammation and promote M2-like macrophage polarization through the IL-10/STAT3/NLRP3 axis in acute lung injury

Zhihao Nie, Qinglu Fan, Wanli Jiang, Shujian Wei, Renwei Luo, Haifeng Hu, Gaoli Liu, Yufei Lei, Songping XieFrontiers in Immunology 2024 · DOI

TL;DR

Researchers have discovered that placental mesenchymal stem cells (pMSCs) can "reprogram" the immune response in acute lung injury (ALI). By secreting IL-10, these stem cells activate a specific signaling pathway (STAT3) that shuts down the NLRP3 inflammasome, effectively flipping macrophages from a pro-inflammatory "attack" mode (M1) to a pro-healing "repair" mode (M2).

What Problem Does This Paper Address?

Acute Lung Injury (ALI) and its more severe form, Acute Respiratory Distress Syndrome (ARDS), are life-threatening conditions with mortality rates hovering around 40%. Currently, clinical treatment is largely limited to supportive care, such as mechanical ventilation, because we lack effective drugs to stop the underlying "cytokine storm."

At the heart of this storm are macrophages. In the early stages of ALI, these immune cells polarize into the M1 phenotype, releasing a flood of inflammatory factors that damage lung tissue. While the body eventually tries to switch to the anti-inflammatory M2 phenotype to repair the damage, this transition often happens too late or too weakly. The authors sought to determine if placental mesenchymal stem cells (pMSCs)—known for their potent immunomodulatory properties—could be used to force this switch and protect the lungs.

Methods

The researchers employed a multi-level approach to validate their hypothesis:

  • In Vivo Modeling: They used a rat model of ALI induced by lipopolysaccharide (LPS), administering pMSCs intratracheally to observe their therapeutic effect on lung architecture and systemic inflammation.
  • In Vitro Modeling: They isolated rat peritoneal macrophages and challenged them with LPS and ATP to simulate the inflammatory environment of a failing lung.
  • Bioinformatics: To find the "molecular bridge" between pMSCs and macrophages, they analyzed an existing transcriptomic dataset (GSE198806) from the Gene Expression Omnibus (GEO) to identify differentially expressed genes.
  • Mechanistic Validation: The team used a suite of molecular tools, including siRNA for gene knockdown, lentiviral vectors for protein overexpression, and specific chemical inhibitors (like MCC950 for NLRP3 and 5,15-DPP for STAT3) to prove that the IL-10/STAT3/NLRP3 axis was indeed the primary driver of the observed effects.

Datasets

The study utilized the GSE198806 dataset from the NCBI Gene Expression Omnibus (GEO). This dataset contains mRNA expression profiles of MSCs cultured alone versus those co-cultured with macrophages. This allowed the researchers to predict which signaling pathways were upregulated during the interaction between stem cells and immune cells.

Key Insights and Ideas

  • The Reprogramming Switch: The most significant insight is that pMSCs don't just "dampen" inflammation; they actively reprogram the macrophage's identity. They push the cells away from the M1 (pro-inflammatory) state and toward the M2 (pro-healing) state.
  • The IL-10/STAT3/NLRP3 Axis: The researchers mapped out a clear linear pathway: pMSCs secrete IL-10, which binds to receptors on macrophages. This triggers the phosphorylation and nuclear translocation of STAT3. Once in the nucleus, STAT3 signaling leads to the inhibition of the NLRP3 inflammasome, a protein complex responsible for the maturation of highly inflammatory cytokines like IL-1β.
  • Placental Advantage: The study highlights the human placenta as a rich, ethically accessible source of MSCs with high proliferative capacity and strong immunosuppressive effects compared to bone marrow-derived cells.

Key Results

  • Reduced Lung Damage: In rat models, pMSC treatment reduced lung injury scores by approximately 40% compared to the LPS-only group.
  • Cytokine Suppression: pMSCs significantly decreased the levels of pro-inflammatory cytokines TNF-α, IL-1β, and IL-18 in bronchoalveolar lavage fluid (BALF) by roughly 32% to 40%.
  • Phenotype Shifting: Flow cytometry and MFI (Median Fluorescence Intensity) analysis showed a marked increase in M2 markers (CD163, CD206) and a decrease in M1 markers (CD40, CD54) following pMSC administration.
  • Molecular Proof: Western blotting confirmed that pMSCs increased STAT3 phosphorylation. When STAT3 was inhibited, the protective effects of the pMSCs were largely lost, proving the pathway's necessity.

Limitations and Future Work

While the results are promising, the authors acknowledge several hurdles:

  • The Feedback Loop: M2 macrophages also secrete IL-10. This makes it difficult to distinguish exactly how much of the therapeutic effect comes directly from the pMSCs versus the "secondary" IL-10 produced by the newly reprogrammed macrophages.
  • Clinical Translation: This study was performed in rats and cell cultures. Human clinical trials are necessary to determine if intratracheal administration of pMSCs is safe and effective in a complex clinical setting.
  • Long-term Effects: The study focused on the acute phase of injury (3 days). Future research is needed to see if pMSC treatment affects long-term lung fibrosis or chronic immune function.

Summary updated

Abstract

The study concluded that pMSCs alleviated lung injury in an LPS-induced ALI model by inhibiting M1 macrophage polarization and proinflammatory factor secretion, while promoting M2 macrophage polarization. This effect was mediated via the IL-10/STAT3/NLRP3 axis, presenting a novel therapeutic pathway for ALI treatment.
BibTeX
@inproceedings{nie2024placental,
  author = {Zhihao Nie and Qinglu Fan and Wanli Jiang and Shujian Wei and Renwei Luo and Haifeng Hu and Gaoli Liu and Yufei Lei and Songping Xie},
  title = {{Placental mesenchymal stem cells suppress inflammation and promote M2-like macrophage polarization through the IL-10/STAT3/NLRP3 axis in acute lung injury}},
  booktitle = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2024.1422355},
}
Figure